{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:59:09Z","timestamp":1715993949314},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T00:00:00Z","timestamp":1416268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Research"],"published-print":{"date-parts":[[2015,7]]},"abstract":"Aim<\/jats:title>This study assessed the efficacy and safety of telaprevir in combination with peginterferon\u2010\u03b1\u20102b (PEG IFN<\/jats:styled-content>) and ribavirin (RBV<\/jats:styled-content>), for Japanese difficult\u2010to\u2010treat patients with hepatitis C<\/jats:styled-content> virus (HCV<\/jats:styled-content>) genotype 2 who had not achieved sustained virological response (SVR<\/jats:styled-content>) during prior treatment.<\/jats:p><\/jats:sec>Methods<\/jats:title>In total, 108 relapsed (median age, 59.0 years) and 10 non\u2010responding (median age, 59.0 years) patients with genotype 2 HCV<\/jats:styled-content> participated. Patients received telaprevir (750\u2009mg, every 8\u2009h) for 12 weeks and PEG IFN<\/jats:styled-content>\/RBV<\/jats:styled-content> for 24 weeks.<\/jats:p><\/jats:sec>Results<\/jats:title>The SVR<\/jats:styled-content> rates for relapsers and non\u2010responders were 88.0% (95\/108) and 50.0% (5\/10), respectively. The SVR<\/jats:styled-content> rates did not differ significantly between patients with rs8099917 TT<\/jats:styled-content> and non\u2010TT<\/jats:styled-content>. The SVR<\/jats:styled-content> rates for relapsers and non\u2010responders with extended rapid viral response (eRVR<\/jats:styled-content>) were 97.6% (82\/84) and 100% (5\/5), respectively. On the other hand, the SVR<\/jats:styled-content> rates for relapsers and non\u2010responders completing the treatment protocol were 98.4% (61\/62) and 100% (5\/5), respectively. The overall safety profiles of telaprevir\u2010based regimens were similar for Japanese patients with genotype 1 and 2 HCV<\/jats:styled-content> infection who experienced treatment failure.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Telaprevir, in combination with PEG IFN<\/jats:styled-content>\/RBV<\/jats:styled-content>, provided a high SVR<\/jats:styled-content> rate for genotype 2 HCV<\/jats:styled-content>, difficult\u2010to\u2010treat patients who had not achieved SVR<\/jats:styled-content> during prior IFN<\/jats:styled-content>\u2010based treatment. The eRVR<\/jats:styled-content> had a strong influence on the cure rate of telaprevir\u2010based therapy. In addition, the continuation of telaprevir\u2010based treatment for up to 24 weeks was a significant predictor of SVR<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hepr.12416","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T11:37:23Z","timestamp":1409917043000},"page":"745-754","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of telaprevir\u2010based therapy for difficult\u2010to\u2010treat patients with genotype 2 chronic hepatitis C<\/scp> in J<\/scp>apan"],"prefix":"10.1111","volume":"45","author":[{"given":"Hiromitsu","family":"Kumada","sequence":"first","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Molecular Science Gunma University Graduate School of Medicine Gunma Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Osaka University Graduate School of Medicine Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Kyushu Medical Center National Hospital Organization Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Nagoya University School of Medicine Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[{"name":"Department of Medical and Molecular Science Division of Frontier Medical Science Programs for Biomedical Research Graduate School of Biomedical Science Hiroshima University Hiroshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Toyota","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Sapporo Kosei General Hospital Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepatology Toranomon Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Nakayasu","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyoko","family":"Ochi","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichimaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Development Division Mitsubishi Tanabe Pharma Corporation Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Saiseikai Suita Hospital Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280632"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904223401602"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01634.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.07.016"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01528.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0949-8"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.051"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042608"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066403"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.00997.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1750-7"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.046"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-77-12-3013"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100380170047"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1206"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24058"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.2.223-235.2000"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12039"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.07.032"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12268"},{"key":"e_1_2_6_29_1","article-title":"The prospective randomized study on telaprevir at 1500\u2009mg or 2250\u2009mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1","author":"Oze T","year":"2014","journal-title":"J Gastroenterol"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12046"}],"container-title":["Hepatology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhepr.12416","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hepr.12416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:38:33Z","timestamp":1696318713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hepr.12416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,18]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/hepr.12416"],"URL":"https:\/\/doi.org\/10.1111\/hepr.12416","archive":["Portico"],"relation":{},"ISSN":["1386-6346","1872-034X"],"issn-type":[{"value":"1386-6346","type":"print"},{"value":"1872-034X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,18]]}}}